Vortioxetine · Trintellix

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Treatment of depression
Product first approved 2019Outside this platform's coveragePMDA
EU
  • Treatment of major depressive episodes in adults.
Product first approved 2013EMA
CA
  • TRINTELLIX (vortioxetine hydrobromide) is indicated for: • the treatment of major depressive disorder (MDD) in adults. The efficacy of TRINTELLIX in providing symptomatic relief of MDD was demonstrated in double-blind, placebo-controlled clinical trials of up to 8 weeks duration (see 14.1 Clinical Trials by Indication, Study Results). The efficacy of TRINTELLIX in maintaining an antidepressant response for up to 24 weeks was demonstrated in a double-blind, placebo-controlled trial in patients with MDD who initially responded to 12-weeks of acute, open label treatment with TRINTELLIX (see...
Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (41)
Major Depressive Disorder
NCT07204314 · Takeda
2025-10-01 – 2029-09-30 · Major Depressive Disorder
What this study did
NCT05104918 · Scotmann Pharmaceuticals
2022-02 – 2022-06 · Major Depressive Disorder
What this study did
NCT02871297 · H. Lundbeck A/S
2016-08-17 – 2022-04-19 · Depressive Disorder, Major
What this study did
NCT03108625 · H. Lundbeck A/S
2017-03-01 – 2020-04-16 · Depressive Disorder, Major
What this study did
NCT02709746 · H. Lundbeck A/S
2016-05 – 2019-07-30 · Depressive Disorder, Major
What this study did
NCT02845349 · Johns Hopkins University
2016-10 – 2018-10 · TBI, Major Depression
What this study did
NCT02389816 · Takeda
2015-04-10 – 2018-03-16 · Major Depressive Disorder
What this study did
NCT02279953 · H. Lundbeck A/S
2014-10 – 2016-04 · Major Depressive Disorder
What this study did
NCT02279966 · H. Lundbeck A/S
2014-10 – 2016-02 · Major Depressive Disorder
What this study did
NCT01364649 · Takeda
2011-06 – 2013-12 · Treatment Outcome
What this study did
NCT01571453 · H. Lundbeck A/S
2012-05 – 2013-10 · Major Depressive Disorder
What this study did
NCT01395147 · Takeda
2011-07 – 2013-05 · Major Depressive Disorder
What this study did
NCT01152996 · Takeda
2010-09 – 2013-05 · Depressive Disorder, Major
What this study did
NCT01422213 · H. Lundbeck A/S
2011-12 – 2013-05 · Major Depressive Disorder
What this study did
NCT01488071 · H. Lundbeck A/S
2012-01 – 2012-12 · Major Depressive Disorder
What this study did
NCT01355081 · Takeda
2011-05 – 2012-12 · Major Depressive Disorder
What this study did
NCT01323478 · H. Lundbeck A/S
2011-04 – 2012-10 · Major Depressive Disorder
What this study did
NCT01179516 · Takeda
2010-08 – 2012-06 · Depressive Disorder, Major
What this study did
NCT01153009 · Takeda
2010-06 – 2012-03 · Depressive Disorder, Major
What this study did
NCT01163266 · Takeda
2010-07 – 2012-01 · Depressive Disorder, Major
What this study did
NCT00707980 · Takeda
2008-06 – 2010-08 · Major Depressive Disorder
What this study did
NCT00694304 · H. Lundbeck A/S
2008-05 – 2010-04 · Major Depressive Disorder
What this study did
NCT00735709 · Takeda
2008-08 – 2009-08 · Major Depressive Disorder
What this study did
NCT00672620 · Takeda
2008-04 – 2008-12 · Major Depressive Disorder
What this study did
NCT00672958 · Takeda
2008-04 – 2008-11 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06561438 · Future University in Egypt
2024-08-26 – 2025-06-07 · Postoperative Pain
What this study did
NCT06025474 · Federico II University
2023-01-01 – 2024-07-24 · Burning Mouth Syndrome
What this study did
NCT04818099 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-10-10 – 2024-04-01 · Radiation Injuries
What this study did
NCT05014919 · H. Lundbeck A/S
2021-08-10 – 2022-04-28 · Depression
What this study did
NCT04035850 · Noam Soreni
2019-08-01 – 2021-08-01 · Hoarding Disorder
What this study did
NCT00788034 · H. Lundbeck A/S
2008-10 – 2010-07 · Generalized Anxiety Disorder
What this study did
Phase 2/3 (4)
Major Depressive Disorder
NCT03053362 · Brain and Cognition Discovery Foundation
2017-05-24 – 2018-08-08 · Major Depressive Disorder, Cognitive Change
What this study did
NCT01255787 · Takeda
2010-11 – 2012-04 · Depressive Disorder, Major
What this study did
Other / comorbidity
NCT04895488 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022-01-20 – 2025-12-20 · Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder
What this study did
NCT03485274 · The University of Hong Kong
2018-07-25 – 2023-04-30 · Cannabis Use Disorder, Depressive State, Anxiety State, Depression, Anxiety Disorders, Pharmacotherapy
What this study did
Phase 2 (14)
Major Depressive Disorder
NCT04498897 · Hanyang University Seoul Hospital
2019-01-25 – 2021-04-04 · Depressive Disorder, Major, Alcoholism
What this study did
NCT03766867 · H. Lundbeck A/S
2018-12-03 – 2019-08-28 · Major Depressive Disorder
What this study did
NCT01564862 · Takeda
2012-04 – 2014-02 · Depressive Disorder, Major
What this study did
NCT00761306 · H. Lundbeck A/S
2007-06 – 2008-10 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06604520 · Johns Hopkins University
2025-03-20 – 2029-09-01 · Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant, Frontotemporal Dementia
What this study did
NCT07284628 · University of Zurich
2026-06-24 – 2029-06 · Glioblastoma
What this study did
NCT07000734 · Washington University School of Medicine
2025-07-28 – 2026-04-30 · Aging, Cognitive Decline, Older Adults, Cardiovascular, Sedentary Behaviors, Immune Senescence, Motor Function
What this study did
NCT05047952 · Brain and Cognition Discovery Foundation
2021-09-16 – 2023-02-22 · Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
What this study did
NCT03598868 · Seoul National University Hospital
2018-08-08 – 2021-09-25 · Bipolar Disorder Depression
What this study did
NCT02528409 · University of Chicago
2016-06 – 2018-11-01 · Binge Eating Disorder
What this study did
NCT02327013 · H. Lundbeck A/S
2014-12 – 2016-09 · Attention Deficit Hyperactivity Disorder
What this study did
NCT01491035 · H. Lundbeck A/S
2012-04 – 2015-06 · Depressive Disorder, Anxiety Disorder
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
Phase 1 (15)
Major Depressive Disorder
NCT05416762 · Seasons Biotechnology (Taizhou) Co., Ltd.
2022-09-19 – 2022-11-25 · Major Depressive Disorder (MDD
What this study did
NCT05416957 · Seasons Biotechnology (Taizhou) Co., Ltd.
2022-09-18 – 2022-10-27 · Major Depressive Disorder (MDD)
What this study did
NCT05417087 · Seasons Biotechnology (Taizhou) Co., Ltd.
2022-06-27 – 2022-09-02 · Major Depressive Disorder (MDD)
What this study did
NCT02454426 · Thomas Jefferson University
2016-04 – 2016-06 · Major Depressive Disorder, Coronary Artery Disease
What this study did
Other / comorbidity
NCT07624357 · ADIUM
2025-03-18 – 2025-05-05 · Bioequivalance
What this study did
NCT04456777 · Alen Greš
2020-07-01 – 2022-07-01 · Cognitive Deficit
What this study did
NCT03884491 · H. Lundbeck A/S
2019-03-18 – 2019-07-22 · Healthy
What this study did
NCT03437564 · Takeda
2018-02-16 – 2018-04-13 · Healthy Adult Participants
What this study did
NCT02386488 · H. Lundbeck A/S
2015-03 – 2015-05 · Pharmacokinetics
What this study did
NCT02170220 · Takeda
2014-07 – 2014-12 · Severe Hepatic Impairment
What this study did
NCT02072278 · H. Lundbeck A/S
2014-02 – 2014-11 · Healthy Men
What this study did
NCT01676571 · H. Lundbeck A/S
2012-10 – 2012-11 · Healthy
What this study did
NCT01299805 · Takeda
2011-03 – 2011-07 · Healthy
What this study did
Phase 4 (27)
Major Depressive Disorder
NCT03779789 · Azienda Ospedaliera Universitaria Integrata Verona
2019-02-01 – 2023-02-28 · Major Depressive Disorder
What this study did
NCT04294654 · H. Lundbeck A/S
2020-02-28 – 2022-07-20 · Major Depressive Disorder, Dementia
What this study did
NCT04288895 · H. Lundbeck A/S
2020-02-20 – 2022-03-12 · Major Depressive Disorder
What this study did
NCT04448431 · H. Lundbeck A/S
2020-06-18 – 2022-02-04 · Major Depressive Disorder
What this study did
NCT03580967 · Todd Doyle
2019-07-01 – 2021-07-01 · Type2 Diabetes, Major Depressive Disorder
What this study did
NCT04220996 · H. Lundbeck A/S
2019-12-27 – 2021-03-09 · MDD, Anxiety Disorders
What this study did
NCT03835715 · H. Lundbeck A/S
2019-02-05 – 2020-02-21 · Major Depressive Disorder
What this study did
NCT02637466 · University of Miami
2016-07 – 2019-07 · Unipolar Major Depression, Stage I, II or III Breast Cancer
What this study did
NCT02371980 · Takeda
2015-02-10 – 2019-04-25 · Major Depressive Disorder
What this study did
NCT03187093 · Oleg Levada
2016-10 – 2019-04 · Major Depressive Disorder
What this study did
NCT02749721 · Rush University Medical Center
2016-12 – 2019-01-31 · Major Depressive Disorder
What this study did
NCT02969876 · Massachusetts General Hospital
2017-08-24 – 2018-08-06 · Depressive Disorder, Major Depression, Depression, Depression, Unipolar
What this study did
NCT02972632 · Takeda
2016-12-22 – 2018-02-06 · Major Depressive Disorder
What this study did
NCT02332954 · Lundbeck Canada Inc.
2015-02 – 2017-07-06 · Major Depressive Disorder
What this study did
NCT02294305 · The Medical Research Network
2014-12 – 2016-11 · Social Anxiety Disorder, Major Depressive Disorder
What this study did
Other / comorbidity
NCT07266545 · Mayo Clinic
2026-02-17 – 2030-12-31 · Unipolar Depression, Bipolar Depression
What this study did
NCT06805266 · Marianna Amboni
2025-02 – 2027-02 · Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise Specified
What this study did
NCT02357797 · Northwell Health
2016-02 – 2024-06-01 · Schizophrenia, Negative Symptoms
What this study did
NCT05481957 · First Affiliated Hospital of Zhejiang University
2022-03-01 – 2023-08-15 · Bipolar Depression
What this study did
NCT04301492 · IRCCS San Raffaele Roma
2019-11-20 – 2023-07-30 · Depression
What this study did
NCT03830827 · Sir Run Run Shaw Hospital
2020-09-01 – 2021-04-30 · Relapse, Cognitive Impairment, Depression
What this study did
NCT02637895 · University of Miami
2016-12 – 2020-02-06 · Post-Traumatic Stress Disorder
What this study did
NCT03272711 · Washington University School of Medicine
2016-08-31 – 2019-01-24 · Age-related Cognitive Decline
What this study did
NCT03978286 · Universidad Juárez Autónoma de Tabasco
2016-06-30 – 2018-06-30 · Depression, Type 2 Diabetes Mellitus
What this study did
NCT02932904 · Takeda
2016-11-21 – 2017-06-09 · Healthy Volunteers
What this study did
NCT02234362 · Massachusetts General Hospital
2015-06-12 – 2016-09-29 · Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
What this study did
NCT02395510 · Siyan Clinical Corporation
2015-05 – 2016-06 · Panic Disorder
What this study did
Early phase / not applicable (1)
Major Depressive Disorder
NCT05866575 · Centre Hospitalier St Anne
2023-09-12 – 2026-11-12 · Major Depressive Disorder
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Major Depressive Disorder
NCT07741331 · Chengdu Kanghong Pharmaceutical Group Co., Ltd.
2026-07 – 2028-12 · Major Depressive Disorder (MDD)
What this study did
NCT03855865 · Naurex, Inc, an affiliate of Allergan plc
2019-07-01 – 2020-12-31 · Depressive Disorder, Major
What this study did

Competitive landscape

This drug's own stage for Major Depressive Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vortioxetine (Trintellix): this drugApprovedSmall moleculeSerotonin transporter + multiple 5-HT receptorsPartial signal
NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed
NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6)
NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51)
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Partial signal
NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7)
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterPartial signal
NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862)
NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
Esketamine (Spravato)ApprovedSmall moleculeNMDA receptorPartial signal
NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88)
NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorWeak signal
NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54)
NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
AmmoxetinePhase 3Small moleculeSerotonin/norepinephrine transporterPartial signal
NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27).
Ansofaxine HydrochloridePhase 3Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001).
AzetukalnerPhase 3Small moleculeKv7 potassium channelnot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
DeupsilocinPhase 3Small molecule5-HT2A receptorPartial signal
NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151)
KH607Phase 3Small moleculeGABA-A receptorPartial signalNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorReliable signal
NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001.
Milsaperidone (VHX-896)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
OsavampatorPhase 3Small moleculeAMPA receptor (positive allosteric modulator)Partial signal
NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082).
Psilocybin (COMP360)Phase 3Small molecule5-HT2A receptorReliable signal
NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001.
NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001)
SeltorexantPhase 3Small moleculeOrexin-2 receptor (OX2R)Partial signal
NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26)
NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporterPartial signal
NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed
D-Cycloserine / Lurasidone (NRX-101)Phase 2/3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Mitizodone PhosphatePhase 2/3Small moleculeSerotonin transporter/5-HT receptorWeak signalNo reviewed efficacy summary in this indication
ACP-211Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancerPartial signal
NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33%
ALTO-203Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)Partial signalNo reviewed efficacy summary in this indication
ALTO-300Phase 2Small moleculeMelatonergic (MT) receptors (agonist) + serotonin receptorWeak signalNo reviewed efficacy summary in this indication
Arketamine (PRT042)Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
AV-101Phase 2Small moleculeNMDA receptorPartial signal
NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed
BI 1569912Phase 2Small moleculeNMDA receptorPartial signal
NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed
NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed
BlixeprodilPhase 2Small moleculeNMDA receptorWeak signalFeatured results are safety only in this race
BPL-003 (mebufotenin Benzoate)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025).
BretisilocinPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)Phase 2Small molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)not yet gradedNo reviewed efficacy summary in this indication
DT-101Phase 2Small moleculeAMPA receptor (positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2Small molecule11-beta-HSD1Partial signal
NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed
Esketamine (CLE-100)Phase 2Small moleculeNMDA receptorPartial signal
NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed
NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed
EvifacotrepPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ForvisirvatPhase 2Small moleculeSIRT6Partial signal
NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed
GlyphAllo (allopregnanolone Prodrug) (SPT-300)Phase 2Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
GW117Phase 2Small moleculeMelatonin MT1/MT2 receptor + 5-HT2C receptorPartial signal
NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed
HS-10353Phase 2Small moleculeGABA-A receptorWeak signal
NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Hypidone (YL-0919)Phase 2Small moleculeSerotonin transporter/5-HT1A receptor/sigma-1 receptorPartial signalNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
JNJ-89495120Phase 2Small moleculeMuscarinic M1 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LiafensinePhase 2Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31)
NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed
LV232Phase 2Small moleculeSerotonin transporter + 5-HT3 receptorWeak signalNo reviewed efficacy summary in this indication
Mebufotenin (5-MeO-DMT) (GH001)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001)
NelivaptanPhase 2Small moleculeVasopressin V1B receptorPartial signal
NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo.
NH102Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporter + 5-HT2A receptorPartial signalNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Partial signal
NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61)
Pramipexole / Ondansetron (ALTO-207)Phase 2Small moleculeDopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptornot yet gradedNo reviewed efficacy summary in this indication
RopanicantPhase 2Small moleculeAlpha4beta2 nicotinic acetylcholine receptorPartial signal
NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met.
NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1.
SPN-820Phase 2Small moleculemTORC1Partial signal
NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed
SPN-821Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (activator)not yet gradedNo reviewed efficacy summary in this indication
VLS-01Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ZelquistinelPhase 2Small moleculeNMDA receptorPartial signal
NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed
ELE-101Phase 1/2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ALA-3000Phase 1Small moleculeNMDA receptorPartial signalFeatured results are safety only in this race
ApimostinelPhase 1Small moleculeNMDAR agonist/modulatorWeak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 9 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trintellix (Vortioxetine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Parkinson Disease, Idiopathic, Freezing of Gait, Depression Not Otherwise SpecifiedNot yet recruiting
Est. primary completion 2026-12 · NCT06805266 · CT.gov ↗
What to watch
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 4Unipolar Depression, Bipolar DepressionRecruiting
Est. primary completion 2028-12-31 · NCT07266545 · CT.gov ↗
What to watch
2029 (3)
May 2029 (1)
Phase 2Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD) …Recruiting
Est. primary completion 2029-05-31 · NCT06604520 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2GlioblastomaRecruiting
Est. primary completion 2029-06 · NCT07284628 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2029-09-30 · NCT07204314 · CT.gov ↗
What to watch

See the full readout calendar ↗